PHARMACOKINETICS
OF
AZLOCILLIN
IN
CHILDREN
WITH
CYSTIC
FIBROSIS
6E1R2OXOIMIDAZOLIDINE1CARBOXAMIDO2PHENYLACETAMIDO
PENICILLANIC
ACID
SODIUM
SALT
AZLOCILLIN
SECUROPEN
WAS
GIVEN
IN
DOSES
OF
100
AND
200
MGKG
BODY
WEIGHT
TO
CHILDREN
WITH
CYSTIC
FIBROSIS
AFTER
INTRAVENOUS
BOLUS
INFECTIONS
THE
SERUM
HALFLIFE
WAS
082

012
H
AFTER
THE
LOWER
DOSE
AND
098

018
H
AFTER
THE
HIGHER
DOSE
THIS
WAS
CONSEQUENT
TO
A
DOSE
LIMITED
ELIMINATION
KINETICS
DUE
TO
LIMITATION
IN
BOTH
RENAL
AND
NONRENAL
PROCESSES
OF
ELIMINATION
UPON
DOUBLING
OF
THE
DOSE
FROM
100
TO
200
MGKG
THE
TOTAL
BODY
CLEARANCE
DROPPED
FROM
1393
TO
510
1H
EVALUATION
OF
DATA
PRESENTED
IN
OTHER
PUBLICATIONS
INDICATE
THAT
A
DOSE
LIMITED
ELIMINATION
KINETICS
IS
THE
NORMAL
SITUATION
FOR
AZLOCILLIN
BESIDES
THE
SERUM
CONCENTRATIONS
OF
PATIENTS
WITH
CYSTIC
FIBROSIS
WERE
CONSIDERABLY
LOWER
THAN
SEEN
IN
THE
HEALTHY
STATE
THE
REASON
IS
FASTER
ELIMINATION
BY
THE
RENAL
ROUTE
IN
CYSTIC
FIBROSIS
